Needham analyst David Saxon has maintained their neutral stance on STAA stock, giving a Hold rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
David Saxon has given his Hold rating due to a combination of factors tied to Staar Surgical’s latest performance and outlook. The company’s first-quarter 2026 revenue matched its earlier preannouncement, and management indicated that second-quarter trends are following typical seasonal patterns, which supports a stable but not clearly accelerating growth narrative.
At the same time, the absence of formal 2026 guidance and lingering uncertainty around the broader business trajectory limit conviction in a more aggressive stance. While Saxon’s view of the company has improved thanks to solid profitability and healthier dynamics in its key markets, these positives are not sufficient to justify a Buy, leading him to keep a neutral Hold recommendation.
In another report released today, Stifel Nicolaus also maintained a Hold rating on the stock with a $31.00 price target.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STAA in relation to earlier this year.